期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗CD22单克隆抗体Epratuzumab治疗非霍奇金淋巴瘤 被引量：1

Epratuzumab as anti-CD22 monocione antibody in treatment of non-Hodgkin＇s iymphoma
原文传递
导出
摘要 epratuzumab是抗CD22的人源化单克隆抗体。CD22分子仅在成熟B淋巴细胞表面表达，约85％的B细胞非霍奇金淋巴瘤表达CD22分子。Ⅰ和Ⅱ期临床研究显示，epratuzumab的毒副作用轻，耐受性良好，对于滤泡型和弥漫大B细胞型淋巴瘤有较好疗效，且可能与美罗华具有协同作用，很有希望成为治疗B细胞非霍奇金淋巴瘤的治疗药物。 Epratuzumab is a humanized anti-CD22 monoclonal antibody. CD22 molecule only expresses on the surface of mature B lymphocytes and appoximately 85% of B cell non-Hodgkin＇ s lymphomas express CD22. Several phase Ⅰ and Ⅱ clinical trials indicate that epratuzumab is well tolerated with mild toxicity , has effective activity in both follicular and diffuse large B cell lymphoma and may has synergetic effects with rituximab,all these demonstrat that epratuzumab may become a promising anti-lymphoma agent.
作者 秦燕（综述） 石远凯（审校） 何小慧（审校）
机构地区 中国协和医科大学中国医学科学院肿瘤医院肿瘤研究所内科
出处 《国际肿瘤学杂志》 CAS 2007年第3期229-231,共3页 Journal of International Oncology
关键词 非霍奇金淋巴瘤 抗体 单克隆 CD22 Non- Hodgkin ＇ s lymphoma Antibodies, monoclonal CD22
分类号 R329.28 [医药卫生—人体解剖和组织胚胎学] R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized an ti-CD22 antibody,in aggressive non-Hodgkin' s lymphoma: Phase Ⅰ/Ⅱ clinical trial results. Clin Cancer Res,2004,10(16) :5327-5334.
  • 2Stein R,Qu Z,Chen S,et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU- 106,and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin' s lymphoma. Clin Cancer Res, 2004, 10 ( 8 ) : 2868-2878.
  • 3Cesano A ,Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol,2003,30( 2 ) :253-257.
  • 4Siegel AB, Goldenberg DM, Cesano A, et al. CD22- directed monoclonal antibody therapy for lymphoma. Semin Oncol,2003,30 (4) :457-464.
  • 5Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res,2003,9( 10 pt 2) :3982S-3990S.
  • 6Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol,2007,44 ( 6 ) :1331 - 1341.
  • 7Leonard JP, Coleman M, Ketas JC, et al. Phase Ⅰ/Ⅱ trial of epratuzumab(humanized anti-CD22 antibody) in indolent non-Hodgkin' s lymphoma. J Clin Oncol,2003,21 (16) :3051-3059.
  • 8Pan D,Moskowitz CH,Zelenetz AD,et al. Rituximab for aggressive non-Hodgkin' s lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J ,2002,8 (5) :371-376.
  • 9Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non- Hodgkin's lymphoma. J Clin Oncol,2005,23(22) :5044-5051.
  • 10Strauss SJ,Morschhauser F,Rech J,et al. Phase Ⅱ multicenter trial of epratuzumab, in combination with rituximab, in refractory or recurrent Non-Hodgkin's lymphoma. J Clin Oncol,2006,24(24) :3880-3886.

同被引文献9

  • 1Vitetta ES, Uhr JW. Monoclonal antibodies as agonists : An expanded role for their use in cancer therapy[ J ]. Cancer Res, 1994, 54 (20) : 5301 - 5309.
  • 2Ghetie MA, Podar EM, Ilgen A, et al. Homodimerization of tumor-re- active monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells [ J ]. Proc Natl Acad Sci U S A, 1997, 94(14): 7509-7514.
  • 3Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lympho- ma cells and synergi ze with a chemo-therapeutic agent and an immu- notoxin[ J]. Blood, 2001, 97(5) : 1392 - 1398.
  • 4Meng R, Smallshaw JE, Pop LM, et al. The evaluation of recombi- nant, chimeric, tetravalent antihuman CD22 antibodies [ J ]. Clin Cancer Res, 2004, 10(4) : 1274 - 1281.
  • 5Bernhard BF, FongY. Long range-inverse PCR (LR-IPCR) : exten- ding the useful range of inverse PCR[J]. Genet Anal, 1996, 13(5) : 123 - 127.
  • 6Duan Z, Li FQ, Wechsler J, et al. A novel notch protein, N2N, tar- geted by neutrophil elastase and implicated in hereditary neutropenia [J]. nol Cell Biol, 2004, 24(1): 58 -70.
  • 7VaUera DA, Brechbiel MW, Burns LJ, et al. Radioimmunotherapy of CD22-expressing daudi tumors in nude mice with a 90Y-labeled anti- CD22 monoclonal antibody [ J ]. Clin Cancer Res, 2005, 11 ( 21 ) : 7920 - 7928.
  • 8冯晶晶,赵媛媛,杨梅,吕茂民.一种快速筛选酵母高表达菌株的新方法[J].生物技术通报,2008,24(6):168-169. 被引量：2
  • 9娄瑞娟,罗利龙,张霞,张瑞刚,宋水山.巴斯德毕赤酵母表达系统的研究进展和前景展望[J].生物学杂志,2010,27(5):73-76. 被引量：20

引证文献1

二级引证文献2

国际肿瘤学杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部